Pablo
Pelegrin Vivancos
Catedraticos de Universidad
Ana
Tapia Abellán
Publicaciones en las que colabora con Ana Tapia Abellán (13)
2024
-
Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β production
Nature Communications, Vol. 15, Núm. 1
2023
-
ASC oligomer favors caspase-1CARD domain recruitment after intracellular potassium efflux
The Journal of cell biology, Vol. 222, Núm. 8
-
Comment on: Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3: Reply
Rheumatology (Oxford, England), Vol. 62, Núm. 5, pp. e168-e169
-
Measuring NLR Oligomerization III: Detection of NLRP3 and NLRC4 Complex by Bioluminescence Resonance Energy Transfer
Methods in molecular biology (Clifton, N.J.), Vol. 2696, pp. 93-103
2022
2021
-
Erratum: Addendum: MCC950 closes the active conformation of NLRP3 to an inactive state (Nature chemical biology (2019) 15 6 (560-564))
Nature chemical biology
-
Sensing low intracellular potassium by NLRP3 results in a stable open structure that promotes inflammasome activation
Science Advances, Vol. 7, Núm. 38
2020
-
Author Correction: Early endosome autoantigen 1 regulates IL-1β release upon caspase-1 activation independently of gasdermin D membrane permeabilization (Scientific Reports, (2019), 9, 1, (5788), 10.1038/s41598-019-42298-4)
Scientific Reports
-
Isolation of functional mature peritoneal macrophages from healthy humans
Immunology and Cell Biology, Vol. 98, Núm. 2, pp. 114-126
2019
-
Early endosome autoantigen 1 regulates IL-1β release upon caspase-1 activation independently of gasdermin D membrane permeabilization
Scientific Reports, Vol. 9, Núm. 1
-
MCC950 closes the active conformation of NLRP3 to an inactive state
Nature Chemical Biology, Vol. 15, Núm. 6, pp. 560-564
2018
-
NLRP3 lacking the leucine-rich repeat domain can be fully activated via the canonical inflammasome pathway
Nature Communications, Vol. 9, Núm. 1
2017
-
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease
Journal of Medicinal Chemistry, Vol. 60, Núm. 9, pp. 3656-3671